



Mid-regional proadrenomedullin

Adrenomedullin: a key marker of endothelial and microcirculatory dysfunction in patients with infection

The microcirculation – the motor of sepsis

The microcirculation in healthy patients

The microcirculation consists of a vast network of small blood vessels whose main purpose is to provide the surrounding tissues with an adequate supply of oxygen and nutrients, as well as to remove waste products, in order to maintain a constant and uninterrupted organ function¹.

The structure and function of the microcirculation is highly heterogeneous between different organs with the total number of capillaries potentially related to the different functional requirements².

The main cell types include endothelial and smooth muscle cells, with involvement of the endothelial cells key in providing a semi-permeable barrier lining the inner surfaces, preventing microorganisms from entering the tissue, and regulating blood flow by controlling the release of mediators and other regulating substances³.

Endothelial cells are connected by junctions which prevent leukocyte emigration and vascular leak, with a glycocalyx layer on the luminal surface serving as a protective barrier between the flowing blood and vessel wall⁴.

Blood flow depends on a pressure gradient along the vascular tree, as well as the amount and distribution of resistance across the microvasculature bed⁵, and therefore a key role in maintaining homeostasis and organ function.




Figure 1: The healthy microcirculation and endothelium. Intact vessel structure allows the constant flow of blood and nutrients to the surrounding tissues and organs, thus maintaining organ function.

The microcirculation during infection

Endothelial dysfunction with vascular leak and tissue edema followed by disruption of the microcirculation is an early, central event in the initial stages of sepsis development⁴.

Bacterial endotoxins, pathogen-derived products and pro-inflammatory factors immediately alter the structure of the endothelial cells, with associated shedding of the glycocalyx, resulting in a subsequent loss in structural integrity, sensitivity and tone⁶⁻⁸. The structural integrity of the endothelial barrier becomes weaker causing endothelial junctions to break down^{9,10}, leading to the movement of fluid from the vessels into the extracellular spaces¹¹⁻¹⁴.

Such processes can result in the development of oedema, local tissue hypoxia, the initial stages of organ dysfunction, and ultimately, organ failure.

Increased endothelial dysfunction and structural damage can lead to a significant decrease in vessel density and in the proportion of perfused vessels, with the greatest changes found in the most severely ill patients^{15,16}. Conversely, microcirculatory function improves more rapidly in surviving patients and those responding to therapy, despite global haemodynamic variables remaining similar irrespective of treatment response or survival outcome¹⁷.




Figure 2: The microcirculation after microbial invasion. Structural changes to the endothelium and a reduced blood flow to the organs result in the early stages of organ dysfunction.

Organ dysfunction and Sepsis Development

The early detection of endothelial damage, microcirculatory dysfunction and tissue hypoxia may allow corrective measures to be taken in order to limit potential organ dysfunction and improve outcome. However, tissue hypoxia is difficult to assess due to non-specific clinical signs and a lack of accurate diagnostic tests. In addition, current measurements of hemodynamic and oxygen-derived parameters do not accurately assess the microcirculation where oxygen delivery is most crucial².

An early identification of endothelial damage and microcirculatory dysfunction is therefore key in preventing sepsis development and progression.


Multiple mechanisms are evident in the microcirculation during sepsis, which include:

- Redistribution of blood flow to more critical body areas
- Endothelial cell barrier and transduction dysregulation
- Increased microvascular permeability and capillary leakage
- Capillary blockage and obstruction
- Disruption of structural and cellular interactions
- Impaired smooth muscle tone

Disruption of these mechanisms can subsequently contribute to:

- A reduction in perfused capillaries and functional density
- The development of heterogeneous abnormalities in microcirculatory blood flow
- A loss of intrinsic vasoregulation in vascular beds
- The initial stages of organ dysfunction and impairment
- Progression towards organ failure







Infection

Microcirculation and
Endothelial damage


Organ Dysfunction




Central nervous
system



Respiratory
system




Renal system



Cardiovascular
system



Coagulation
system



Hepatic system



Sepsis-related Organ Failure Assessment (SOFA) score ≥ 2

Sepsis

Life-threatening organ dysfunction caused by a dysregulated host response to infection

Septic Shock

A subset of sepsis in which particularly profound circulatory, cellular and metabolic anomalies are associated with a greater risk of mortality than with sepsis alone

Multiple Organ Failure



Figure 3: Overview of disease progression from an initial infection to sepsis and septic shock.

Adrenomedullin – the key to the microcirculation

Adrenomedullin has been shown to play a significant role in many physiological processes, including cellular growth, development, chemotaxis and migration¹⁸⁻²³. It also has potent anti-microbial activity, eliciting its response through membrane channel formation and lysis, as well as anti-apoptotic actions²⁴⁻²⁷. However, two main properties are of significant interest in sepsis:

Microcirculation and vascular endothelial barrier function


Increasing evidence suggests that Adrenomedullin is produced in order to reduce vascular permeability and increase the stability of the microcirculation. Recent studies have shown that Adrenomedullin may be a good surrogate marker for predicting sodium and extracellular fluid overload in a variety of critically ill intensive care patients²⁸, with a strong correlation to the severity of plasma leakage in patients with Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS)²⁹.

Further experimental evidence has found that Adrenomedullin reduces vascular hyperpermeability³⁰ and stabilises

endothelial barrier function³¹, and can redistribute blood flow back to sites which have experienced a lack of perfusion and oxygenation due to alpha-toxin infusion³².

Adrenomedullin may therefore accurately reflect the developing pathophysiological changes occurring in the microcirculation and microvasculature during disease onset. An early assessment of Adrenomedullin levels could be useful in evaluating disease progression or assessing the efficacy of therapeutic interventions on the host response.

- Protects against endothelial permeability and consequent organ damage^{3,30,34}
- Protective effects in organs in response to bacterial induced shock^{35,36}
- Stabilization of microcirculation in inflammation - a hallmark of organ failure³²
- Restoration of endothelial stability in infected organs due to prevention of undesired inflammatory decompartmentalization³⁷
- Increased in the early stages of organ dysfunction³³






Vasodilation

Perhaps one of the most well-known features of Adrenomedullin are its vasodilatory properties. Increased circulating concentrations have been shown to result in a potent and sustained hypotension, mainly due to the generation of Nitric Oxide, with transient concentration surges contributing to the dramatic hypotension and vascular collapse found in patients with acute episodes of systemic capillary leak syndrome³⁸.

Acute or chronic increases in Adrenomedullin can also result in a significant decrease in total peripheral resistance, accompanied by a fall in blood pressure, as well as an increased heart rate, cardiac output and stroke volume.

Increases or decreases in Adrenomedullin levels, therefore, can have a significant effect on the volume of blood supply to organs in specific disease settings.

- Key mediator of vascular tone regulation resulting in an intense, prolonged vasorelaxation and hypotension³⁹⁻⁴⁴
- Widespread production helps maintain blood supply to individual organs^{39,41,45}
- Localized cellular production and release to meet specific perfusion requirements of individual organs^{46,47}
- Significant role in hemorrhagic and endotoxic shock⁴⁸⁻⁵⁰, pulmonary hypertension⁵¹, hypertrophy^{52,53}, hypoxia⁵⁴⁻⁵⁹, oxidative stress⁶⁰, ischaemic myocardial injury⁶¹⁻⁶⁴ and ischaemic injury and organ failure^{65,66}



Mid-regional proadrenomedullin

Reliable measurement of Adrenomedullin is complicated by a number of issues, such as a short half-life, a fast metabolism, low concentrations, a rapid degradation by proteases, and binding to compliment factor H. Accordingly, levels of Adrenomedullin can therefore be typically underestimated. The measurement of mid-regional proadrenomedullin provides a solution to these problems.

Biosynthesis of MR-proADM

MR-proADM is a fragment of 48 amino acids which splits from the proADM molecule in a ratio of 1:1 with Adrenomedullin, and proportionally represents the levels and activity of Adrenomedullin. Its biological inactivity means that it is not involved in the binding to vessel walls and surfaces

found with Adrenomedullin. Its longer half-life of several hours and biological inactivity results in a more accurate estimation of plasma concentration levels than using ADM.




Figure 4: Structure of the preproADM molecule and generation of the related MR-proADM and Adrenomedullin peptides

Thermo Scientific™ B·R·A·H·M·S™ MR-proADM KRYPTOR™ kinetics and features

MR-proADM levels have been shown to be rapidly elevated immediately after the administration of LPS, reaching significantly increased levels after only 2 hours^{67,68} and almost doubling in concentration⁶⁸. Concentrations were found to subsequently peak at 4 hours^{67,68} before decreasing.

Clinical utility of MR-proADM as a biomarker

- Indicator of microcirculatory status and organ dysfunction
- Rapid release in response to infection and inflammation
- Stable molecule, equimolar to native ADM

**MR proADM is a valuable biomarker for early
detection of organ dysfunction and outcome**




Figure 4: Significant increases in MR-proADM levels can be observed 2 hours after a single LPS injection (4ng/kg IV) (adapted from de Kruif et al. 2008)⁶⁸.



- Levels are **not** **influenced** by food or water intake⁶⁹



- No significant **gender** related differences⁶⁹



- **Stability of up to 72 hours** in EDTA plasma at room temperature and over four freeze/thaw cycles⁶⁹



- Well **documented** for clinical use



- **Rapidly available** to aid timely clinical decision-making using the KRYPTOR™ platform*

* assay incubation time 29 mins and small sample volume (26 µL in EDTA plasma)

Figure 5: Key features of the B·R·A·H·M·S MR-proADM KRYPTOR assay

References

1. Ince C. The microcirculation is the motor of sepsis. *Crit Care*. 2005;9 Suppl 4:S13-19.
2. Hernandez G, Bruhn A, Ince C. Microcirculation in sepsis: new perspectives. *Curr Vasc Pharmacol*. 2013;11(2):161-169.
3. Vallet B. Endothelial cell dysfunction and abnormal tissue perfusion. *Crit Care Med*. 2002;30(5 Suppl):S229-234.
4. Lee WL, Slutsky AS. Sepsis and endothelial permeability. *N Engl J Med*. 2010;363(7):689-691.
5. Klijn E, Den Uil CA, Bakker J, Ince C. The heterogeneity of the microcirculation in critical illness. *Clin Chest Med*. 2008;29(4):643-654, viii.
6. Baker CH, Wilmoth FR. Microvascular responses to *E. coli* endotoxin with altered adrenergic activity. *Circ Shock*. 1984;12(3):165-176.
7. Price SA, Spain DA, Wilson MA, Harris PD, Garrison RN. Subacute sepsis impairs vascular smooth muscle contractile machinery and alters vasoconstrictor and dilator mechanisms. *J Surg Res*. 1999;83(1):75-80.
8. Legrand M, Klijn E, Payen D, Ince C. The response of the host microcirculation to bacterial sepsis: does the pathogen matter? *J Mol Med (Berl)*. 2010;88(2):127-133.
9. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. *Semin Immunopathol*. 2017;39(5):517-528.
10. Fox ED, Heffernan DS, Cioffi WG, Reichner JS. Neutrophils from critically ill septic patients mediate profound loss of endothelial barrier integrity. *Crit Care*. 2013;17(5):R226.
11. Cervinka WH, Cooper D, Kriegelstein CF, Ross CR, McCord JM, Granger DN. Superoxide mediates endotoxin-induced platelet-endothelial cell adhesion in intestinal venules. *Am J Physiol Heart Circ Physiol*. 2003;284(2):H535-541.
12. Martins PS, Kallas EG, Neto MC, Dalboni MA, Blecher S, Salomao R. Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock. *Shock*. 2003;20(3):208-212.
13. Victor VM, Rocha M, De la Fuente M. Immune cells: free radicals and antioxidants in sepsis. *Int Immunopharmacol*. 2004;4(3):327-347.
14. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. *Curr Opin Crit Care*. 2003;9(2):143-151.
15. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. *Am J Respir Crit Care Med*. 2002;166(1):98-104.
16. Trzeciak S, Dellinger RP, Parrillo JE, et al. Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. *Ann Emerg Med*. 2007;49(1):88-98, 98 e81-82.
17. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit Care Med*. 2004;32(9):1825-1831.
18. Kohno M, Yokokawa K, Kano H, et al. Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. *Hypertension*. 1997;29(6):1309-1313.
19. Fernandez S, Knopf MA, McGillis JP. Calcitonin-gene related peptide (CGRP) inhibits interleukin-7-induced pre-B cell colony formation. *J Leukoc Biol*. 2000;67(5):669-676.
20. Kamoi H, Kanazawa H, Hirata K, Kurihara N, Yano Y, Otani S. Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. *Biochem Biophys Res Commun*. 1995;211(3):1031-1035.
21. Kohno M, Yokokawa K, Yasunari K, et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. *Circulation*. 1998;98(4):353-359.
22. Iwasaki H, Eguchi S, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation. *Endocrinology*. 1998;139(8):3432-3441.
23. Withers DJ, Coppock HA, Seufferlein T, Smith DM, Bloom SR, Rozengurt E. Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of cAMP in Swiss 3T3 cells. *FEBS Lett*. 1996;378(1):83-87.
24. Allaker RP, Zihni C, Kapas S. An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. *FEMS Immunol Med Microbiol*. 1999;23(4):289-293.
25. Yin H, Chao L, Chao J. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. *Hypertension*. 2004;43(1):109-116.
26. Allaker RP, Grosvenor PW, McAnerney DC, et al. Mechanisms of adrenomedullin antimicrobial action. *Peptides*. 2006;27(4):661-666.
27. Marutsuka K, Nawa Y, Asada Y, et al. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) are present in human colonic epithella and exert an antimicrobial effect. *Exp Physiol*. 2001;86(5):543-545.
28. Vigue B, Leblanc PE, Moati F, et al. Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study. *Crit Care*. 2016;20(1):363.
29. Michels M, Djamiatun K, Faradz SM, Koenders MM, de Mast Q, van der Ven AJ. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. *J Clin Virol*. 2011;50(1):8-12.
30. Temmesfeld-Wollbrück B, Brell B, David I, et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. *Intensive Care Med*. 2007;33(4):703-710.
31. Temmesfeld-Wollbrück B, Hocke AC, Suttrop N, Hippenstiel S. Adrenomedullin and endothelial barrier function. *Thromb Haemost*. 2007;98(5):944-951.
32. Brell B, Hippenstiel S, David I, et al. Adrenomedullin treatment abolishes ileal mucosal hypoperfusion induced by *Staphylococcus aureus* alpha-toxin--an intravital microscopic study on an isolated rat ileum. *Crit Care Med*. 2005;33(12):2810-2016.
33. Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. *Am J Respir Crit Care Med*. 1999;160(1):132-136.
34. Muller-Redetzky HC, Will D, Hellwig K, et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. *Crit Care*. 2014;18(2):R73.
35. Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. *Am J Pathol*. 2006;168(6):1921-1930.
36. Carrizo GJ, Wu R, Cui X, Dwivedi AJ, Simms HH, Wang P. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. *Surgery*. 2007;141(2):245-253.

37. Pugin J. Adrenomedullin: a vasodilator to treat sepsis? *Crit Care*. 2014;18(3):152.
38. Xie Z, Chen WS, Yin Y, et al. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). *J Leukoc Biol*. 2018.
39. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. *Biochem Biophys Res Commun*. 1993;192(2):553-560.
40. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. *Crit Care*. 2005;9(6):R816-824.
41. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. *Endocr Rev*. 2000;21(2):138-167.
42. Landry DW, Oliver JA. Insights into shock. *Sci Am*. 2004;290(2):36-41.
43. Ishiyama Y, Kitamura K, Ichiki Y, et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. *Eur J Pharmacol*. 1993;241(2-3):271-273.
44. Ishiyama Y, Kitamura K, Ichiki Y, et al. Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. *Clin Exp Pharmacol Physiol*. 1995;22(9):614-618.
45. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. *Peptides*. 2001;22(11):1693-1711.
46. Elsasser TH, Kahl S. Adrenomedullin has multiple roles in disease stress: development and remission of the inflammatory response. *Microsc Res Tech*. 2002;57(2):120-129.
47. Takahashi K, Nakayama M, Totsune K, et al. Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. *J Neurochem*. 2000;74(1):99-103.
48. Fujioka S, Ono Y, Kangawa K, Okada K. Plasma concentration of adrenomedullin is increased in hemorrhagic shock in dogs. *Anesth Analg*. 1999;88(2):326-328.
49. Kikumoto K, Kubo A, Hayashi Y, et al. Increased plasma concentration of adrenomedullin in patients with subarachnoid hemorrhage. *Anesth Analg*. 1998;87(4):859-863.
50. Ono Y, Kojima M, Okada K, Kangawa K. cDNA cloning of canine adrenomedullin and its gene expression in the heart and blood vessels in endotoxin shock. *Shock*. 1998;10(4):243-247.
51. Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. *Clin Sci (Lond)*. 1999;96(1):33-39.
52. Tsuruda T, Kato J, Kitamura K, et al. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. *Hypertension*. 1998;31(1 Pt 2):505-510.
53. Yoshihara F, Nishikimi T, Horio T, et al. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. *Eur J Pharmacol*. 1998;355(1):33-39.
54. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. *J Biol Chem*. 1998;273(28):17787-17792.
55. Cejudo-Martin P, Morales-Ruiz M, Ros J, et al. Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. *Hepatology*. 2002;36(5):1172-1179.
56. Nagata D, Hirata Y, Suzuki E, et al. Hypoxia-induced adrenomedullin production in the kidney. *Kidney Int*. 1999;55(4):1259-1267.
57. Trollmann R, Schoof E, Beinder E, Wenzel D, Rascher W, Dotsch J. Adrenomedullin gene expression in human placental tissue and leukocytes: a potential marker of severe tissue hypoxia in neonates with birth asphyxia. *Eur J Endocrinol*. 2002;147(5):711-716.
58. Hofbauer KH, Jensen BL, Kurtz A, Sandner P. Tissue hypoxigenation activates the adrenomedullin system in vivo. *Am J Physiol Regul Integr Comp Physiol*. 2000;278(2):R513-519.
59. Nakayama M, Takahashi K, Murakami O, Shirato K, Shibahara S. Induction of adrenomedullin by hypoxia in cultured human coronary artery endothelial cells. *Peptides*. 1999;20(6):769-772.
60. Ando K, Ito Y, Kumada M, Fujita T. Oxidative stress increases adrenomedullin mRNA levels in cultured rat vascular smooth muscle cells. *Hypertens Res*. 1998;21(3):187-191.
61. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. *N Engl J Med*. 2005;353(13):1332-1341.
62. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. *Heart*. 1999;81(5):483-487.
63. Oie E, Vinge LE, Yndestad A, Sandberg C, Groggaard HK, Attramadal H. Induction of a myocardial adrenomedullin signaling system during ischemic heart failure in rats. *Circulation*. 2000;101(4):415-422.
64. Vijay P, Szekely L, Aufiero TX, Sharp TG. Coronary sinus adrenomedullin rises in response to myocardial injury. *Clin Sci (Lond)*. 1999;96(4):415-420.
65. Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. *J Clin Invest*. 1994;94(5):2158-2161.
66. Wang X, Yue TL, Barone FC, et al. Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. *Proc Natl Acad Sci U S A*. 1995;92(25):11480-11484.
67. Vila G, Resl M, Stelzeneder D, et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. *J Appl Physiol* (1985). 2008;105(6):1741-1745.
68. de Kruif MD, Lemaire LC, Giebelen IA, et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. *Intensive Care Med*. 2008;34(3):518-522.
69. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. *Clin Chem*. Oct 2005;51(10):1823-1829.



Assess disease severity and progression with B·R·A·H·M·S MR-proADM KRYPTOR™

Find out more about the clinical use of MR-proADM in our
Emergency Department and Intensive Care Unit brochures

Clinical Diagnostics

Thermo Fisher Scientific
B·R·A·H·M·S GmbH
Neuendorfstr. 25
16761 Hennigsdorf
Deutschland

+49 (0)3302 883 0
+49 (0)3302 883 100 Fax
info.brahms@thermofisher.com
www.thermoscientific.com/brahms

Find out more at [thermoscientific.com/proadrenomedullin](https://www.thermoscientific.com/proadrenomedullin)

Product is CE marked but not 510(k)-cleared and not [yet] available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

© 2019 Thermo Fisher Scientific Inc. All rights reserved.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Specifications, terms and pricing are subject to change.

The manufacture and/or use of this product is covered by one or more of the following patents: EP1488209, MX255044, JP4602321, CN1759319, HK1089232, JP5021791, US9541549, US9885709, EP2347266, CN102317790, HK1163813, IN283666, JP5584695, US9012151, JP5711131, IN289480

ThermoFisher
SCIENTIFIC